Aarti Drugs Ltd (AARTIDRUGS)
₹435.20
Mkt cap
₹3,972 Cr
P/E ratio
20.60
P/B
2.56
Div yield
0.46%
ROE
13.40%
ROCE
12.00%
EPS (TTM)
₹21.13
Book value
₹170
52W range
319–534
Sector
Healthcare
Price history
Previous close
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1] It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]
NSE AARTIDRUGSBSE 524348
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−18.50% from high₹435
₹319+36.45% from low₹534
Current
₹435.20
Prev close
₹449.00
Day
−3.07%
Price performance
1D
−2.23%
1W
+17.10%
1M
+2.43%
3M
+6.35%
6M
+17.58%
1Y
−13.54%
YTD
+5.90%
Financials
Revenue, profit & margin
P/E ratio
20.6×
AARTIDRUGS is 40% below the sector median of 34.4×
AARTIDRUGS20.6×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 661 | 642 | 606 | 620 | 555 | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 | |
| Expenses | 577 | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 | |
| Operating Profit | 84 | 76 | 70 | 86 | 65 | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 | |
| OPM % | 13% | 12% | 12% | 14% | 12% | 11% | 11% | 14% | 13% | 13% | 9% | 13% | 14% | |
| Other Income | 1 | 1 | 2 | 1 | 1 | 1 | 12 | 2 | 0 | 0 | 1 | 1 | -1 | |
| Interest | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 | |
| Depreciation | 13 | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 | |
| Profit before tax | 64 | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 | |
| Tax % | 24% | 30% | 29% | 26% | 24% | 24% | 27% | 12% | -6% | 25% | -40% | 21% | 28% | |
| Net Profit | 48 | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 | |
| EPS in Rs | 5.17 | 4.31 | 3.99 | 5.15 | 3.62 | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | 5.50 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −3.67% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 31 Jul '26◦ |
| Earnings day | −3.67% |
| +1 day | −2.06% |
| +5 days | −0.05% |
| +15 days | −0.40% |
| +30 days | +0.85% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202654.07%Promoter
Promoters54.07%0.36
FIIs2.26%0.74
DIIs10.24%0.05
Public33.42%0.34
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Aarti Drugs | ₹435.20 | 20.61 | 3,972 | 0.46% | 50 | −4.14% | 703 | +19.01% | 12.03% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts66
PPTSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Q2 H1 FY27 Earning Conference Call IntimationBoard Meeting Intimation for Audited Financial Results For The Quarter And Half Year Ended September 30, 2026 27 Oct - Board meeting on November 3, 2026 to approve audited Q2 and half-year FY27 results.Crisil ESG Rating 8 Oct - Crisil ESG assigned Aarti Drugs a ‘Crisil ESG 61’ Strong rating for FY2025-26.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Regulation 74(5) certificate submitted for quarter ended September 30, 2026.Details Of Authorized Persons Under Regulation 30(5) Of The SEBI LODR Regulations, 2015 1 Oct - Aarti Drugs names authorized disclosure officers under Regulation 30(5) effective October 1, 2026.